Fulgent Genetics, Inc. (FLGT) CSO has 1,645 shares withheld on RSU vesting

Rhea-AI Filing Summary

Fulgent Genetics, Inc. (FLGT) reports that Chief Scientific Officer Hanlin Gao had 1,645 shares of Common Stock withheld on July 26, 2026 to satisfy tax withholding obligations from the vesting of restricted stock units assumed in a prior merger, leaving him with 988,729 shares directly held.

Insider Trade Summary

Net Seller: 1,645 shares

Net Sell 1 txn

Insider Gao Hanlin

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	1,645	$19.67	$32K

Holdings After Transaction: Common Stock — 988,729 shares (Direct)

Footnotes (1)

1. F1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

Key Figures

Shares withheld for taxes: 1645.0000 shares Tax withholding price: $19.6700 per share Shares held after transaction: 988729.0000 shares

3 metrics

Shares withheld for taxes 1645.0000 shares Common Stock withheld on July 26, 2026 to satisfy tax obligations on vested RSUs

Tax withholding price $19.6700 per share Per-share value used for the tax-withholding disposition of 1,645 shares

Shares held after transaction 988729.0000 shares Direct Common Stock holdings by Hanlin Gao following the tax-withholding event

Key Terms

restricted stock units, tax withholding obligations, Agreement and Plan of Merger

3 terms

restricted stock units financial

"upon the vesting of certain restricted stock units assumed"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld from the reporting person to satisfy the tax withholding obligations"

Agreement and Plan of Merger regulatory

"assumed pursuant to the Agreement and Plan of Merger, dated"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 04:32 PM Accepted by SEC EDGAR 07/28/2026 - 04:32 PM Learn about SEC filing dates

FAQ

What insider transaction did FLGT’s Hanlin Gao report?

Hanlin Gao, Chief Scientific Officer of Fulgent Genetics, reported a tax-withholding disposition of 1,645 Common Stock shares on July 26, 2026. The shares were withheld to satisfy tax obligations triggered by the vesting of restricted stock units assumed in an earlier merger.

How many FLGT shares were withheld from Hanlin Gao and at what value?

The transaction shows 1,645 Fulgent Genetics shares withheld at $19.67 per share. This value reflects the per-share price used to determine the tax withholding amount tied to the vesting of restricted stock units from the prior merger-related awards.

Why were FLGT shares withheld from Hanlin Gao in this transaction?

The shares were withheld to satisfy tax withholding obligations arising when restricted stock units vested. These RSUs were assumed under an Agreement and Plan of Merger dated November 7, 2022, involving Fulgent Genetics, FG Merger Sub, Fulgent Pharma Holdings, and certain stockholders.

How many FLGT shares does Hanlin Gao hold after this tax-withholding event?

After the reported tax-withholding disposition, Hanlin Gao directly holds 988,729 shares of Fulgent Genetics Common Stock. This post-transaction figure reflects his remaining direct equity position following the 1,645 shares withheld for taxes on the vested RSUs.

Was Hanlin Gao’s FLGT transaction executed under a Rule 10b5-1 trading plan?

The report’s Rule 10b5-1 checkbox is not marked as a plan transaction. The disclosure only describes a tax-withholding disposition related to RSU vesting and does not indicate that this specific event occurred under a pre-arranged trading plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gao Hanlin

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CALIFORNIA 91731

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/26/2026		F		1,645(1)	D	$19.67	988,729	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units assumed pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 by and among Fulgent Genetics, Inc., FG Merger Sub, Inc., Fulgent Pharma Holdings, Inc., and the stockholders listed therein. These awards were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.

	/s/ Paul Kim as Attorney-in-Fact	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)